Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Preliminary experience with parenteral mecillinam.

A P Menday, B T Marsh

    Current Medical Research and Opinion
    |January 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Symptomatic vaginal candidiasis after pivmecillinam and norfloxacin treatment of acute uncomplicated lower urinary tract infection.

    International journal of antimicrobial agents·2002
    Same author

    Patient attitudes to topical antipsoriatic treatment with calcipotriol and dithranol.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2000
    Same author

    Comparison of pivmecillinam and cephalexin in acute uncomplicated urinary tract infection.

    International journal of antimicrobial agents·2000
    Same author

    A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis.

    The British journal of dermatology·1999
    Same author

    Long-term use of the low molecular weight heparin tinzaparin in haemodialysis.

    Haemostasis·1996
    Same author

    Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma.

    British journal of obstetrics and gynaecology·1990
    Same journal

    Clinical and healthcare resource utilization outcomes following revision knee arthroplasty with and without a gradually reducing radius revision knee system.

    Current medical research and opinion·2026
    Same journal

    Medication adherence measurement methods and their reported relationship with medication safety outcomes: a scoping review.

    Current medical research and opinion·2026
    Same journal

    BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia.

    Current medical research and opinion·2026
    Same journal

    Comparative efficacy of tislelizumab + FOLFOX or CAPOX for gastric/gastroesophageal junction adenocarcinoma: an exploratory matching-adjusted indirect comparison.

    Current medical research and opinion·2026
    Same journal

    Seizing the opportune moment: early use of antiplatelet therapy for thrombolysis.

    Current medical research and opinion·2026
    Same journal

    A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma.

    Current medical research and opinion·2026
    See all related articles

    Parenteral mecillinam showed a 68% success rate in treating severe Gram-negative infections. Early mecillinam treatment without other antibiotics led to better patient outcomes.

    Area of Science:

    • Infectious Diseases
    • Pharmacology
    • Clinical Medicine

    Background:

    • Severe Gram-negative infections pose significant treatment challenges.
    • Mecillinam is an antibiotic with activity against Gram-negative bacteria.

    Purpose of the Study:

    • To evaluate the clinical effectiveness of parenteral mecillinam in severe Gram-negative infections.
    • To assess the impact of combination therapy on mecillinam's efficacy.

    Main Methods:

    • Review of case reports from 26 patients with severe Gram-negative infections.
    • Analysis of treatment outcomes for patients receiving parenteral mecillinam, with or without concurrent antibiotics.

    Main Results:

    • A beneficial clinical effect was observed in 68% (17/25) of patients treated with parenteral mecillinam.

    Related Experiment Videos

  • Patients receiving mecillinam as monotherapy showed a better response compared to those on combination therapy.

    • Conclusions:

    • Parenteral mecillinam demonstrates potential as a treatment option for severe Gram-negative infections.
    • Early administration of mecillinam, ideally without prior antibiotics, may improve clinical outcomes.